Whole-section Immune and Molecular Phenotyping Identifies Distinct PD-L1 and p53 Phenotypic Subsets in Advanced Ovarian Carcinosarcoma

Ovarian carcinosarcoma (OCS) is a rare, aggressive malignancy with poor prognosis and limited treatment options. This study explored associations between programmed death-ligand 1 (PD-L1) expression, p53 phenotypic subclasses, mismatch repair (MMR) status, BRCA1/2 status, and clinical outcomes in advanced OCS. Twenty-one FIGO stage III-IV OCSs from a single institution were examined using whole-section immunohistochemistry for PD-L1, p53, and MMR proteins. Targeted next-generation sequencing for TP53 was carried out in selected cases. Clinical data were collected alongside germline/somatic BRCA1/2 results. PD-L1 was scored using the combined positive score or tumor proportion score. Median overall survival was 33 mo; 81% of patients experienced recurrence. PD-L1 positivity (combined positive score ≥1 and tumor proportion score ≥1%) was observed in 47.6% of tumors and demonstrated associations with improved survival. Aberrant p53 expression was identified in 95.2% of cases, with a potential association between the p53 null phenotype and increased PD-L1 expression in both carcinomatous and sarcomatous tumor components. All tumors were MMR proficient. BRCA1/2 mutations were identified in 28.6% of tested patients (germline or somatic), although incomplete testing limited interpretation. Whole-section assessment identified biologically distinct phenotypes within OCS. These findings provide a rationale for future translational studies aimed at identifying actionable clinical biomarkers and refining patient stratification in this challenging disease.

Authors

Institutions

Publication Details

Journal
International Journal of Gynecological Pathology
Published
2026-11-12
DOI
https://doi.org/10.1097/pgp.0000000000001229
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Whole-section Immune and Molecular Phenotyping Identifies Distinct PD-L1 and p53 Phenotypic Subsets in Advanced Ovarian Carcinosarcoma

Narinder Gahir, Inga Chen, Yong Sheng Tan, Michela Quaranta et al.
International Journal of Gynecological Pathology
Ovarian cancer diagnosis and treatment
article

Whole-section Immune and Molecular Phenotyping Identifies Distinct PD-L1 and p53 Phenotypic Subsets in Advanced Ovarian Carcinosarcoma

Narinder Gahir, Inga Chen, Yong Sheng Tan, Michela Quaranta, Alexandros Laios, Diederick De Jong, Leanne Galvin, Nicolas Michel Orsi, Michele Cummings, Luke Broadhurst, Katie Allen
article en

Abstract

Ovarian carcinosarcoma (OCS) is a rare, aggressive malignancy with poor prognosis and limited treatment options. This study explored associations between programmed death-ligand 1 (PD-L1) expression, p53 phenotypic subclasses, mismatch repair (MMR) status, BRCA1/2 status, and clinical outcomes in advanced OCS. Twenty-one FIGO stage III-IV OCSs from a single institution were examined using whole-section immunohistochemistry for PD-L1, p53, and MMR proteins. Targeted next-generation sequencing for TP53 was carried out in selected cases. Clinical data were collected alongside germline/somatic BRCA1/2 results. PD-L1 was scored using the combined positive score or tumor proportion score. Median overall survival was 33 mo; 81% of patients experienced recurrence. PD-L1 positivity (combined positive score ≥1 and tumor proportion score ≥1%) was observed in 47.6% of tumors and demonstrated associations with improved survival. Aberrant p53 expression was identified in 95.2% of cases, with a potential association between the p53 null phenotype and increased PD-L1 expression in both carcinomatous and sarcomatous tumor components. All tumors were MMR proficient. BRCA1/2 mutations were identified in 28.6% of tested patients (germline or somatic), although incomplete testing limited interpretation. Whole-section assessment identified biologically distinct phenotypes within OCS. These findings provide a rationale for future translational studies aimed at identifying actionable clinical biomarkers and refining patient stratification in this challenging disease.

International Journal of Gynecological Pathology
University of Leeds (GB), St James's University Hospital (GB)
Good health and well-being
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon